The hypoxia inducible factors (Hifs) are evolutionarily conserved transcriptional factors that control homeostatic responses to low oxygen. In developing bone, Hif-1 generated signals induce angiogenesis necessary for osteoblast specification, but in mature bone, loss of Hif-1 in osteoblasts resulted in a more rapid accumulation of bone. These findings suggested that Hif-1 exerts distinct developmental functions and acts as a negative regulator of bone formation. To investigate the function of Hif-1a in osteoanabolic signaling, we assessed the effect of Hif-1a loss-of-function on bone formation in response to intermittent parathyroid hormone (PTH). Mice lacking Hif-1a in osteoblasts and osteocytes form more bone in response to PTH, likely through a larger increase in osteoblast activity and increased sensitivity to the hormone. Consistent with this effect, exposure of primary mouse osteoblasts to PTH resulted in the rapid induction of Hif-1a protein levels via a post-transcriptional mechanism. The enhanced anabolic response appears to result from the removal of Hif-1a-mediated suppression of b-catenin transcriptional activity. Together, these data indicate that Hif-1a functions in the mature skeleton to restrict osteoanabolic signaling. The availability of pharmacological agents that reduce Hif-1a function suggests the value in further exploration of this pathway to optimize the therapeutic benefits of PTH.
INTRODUCTION
Parathyroid hormone (PTH), an 84-amino-acid polypeptide, is an essential regulator of mineral homeostasis and bone remodeling. Released by the chief cells of the parathyroid gland in response to deviations in serum calcium levels, PTH primarily acts on kidney and bone to increase calcium reabsorption and liberate calcium from bone matrix, respectively. 1 Additionally, intermittent PTH administration is recognized for its anabolic effects in bone, and the first 34 amino acids of the hormone form the basis for the only Food and Drug Administration-approved anabolic agent to treat osteoporosis. [2] [3] [4] The anabolic actions of PTH have been extensively studied in laboratory rodent models. 5 Through its actions on the PTH receptor, 6 expressed by osteoblasts and osteocytes, histological analyses suggest that intermittent PTH increases bone acquisition by increasing the number of bone-forming osteoblasts. [7] [8] [9] More recent molecular analyses have attempted to identify signaling mechanisms and components that allow PTH to reduce bone cell apoptosis, 9 stimulate progenitor cell recruitment 10 and activate formerly quiescent bone lining cells. 11 In addition to the activation of cyclic AMP (cAMP) and protein kinase A signaling, 12 components of the insulin-like growth factor pathway, [13] [14] [15] the transforming growth factor-b pathway 10, 16 and Wnt/b-catenin signaling [17] [18] have all been demonstrated to be required for the full osteo-anabolic response to PTH. The identification of factors or signaling mechanisms that inhibit bone formation after PTH administration has been less common, [19] [20] but examining such mechanisms could facilitate the development of strategies to increase the therapeutic efficacy of intermittent PTH. Hypoxia inducible factor-1 (Hif-1) is most widely recognized for its role in the cellular response to molecular oxygen levels. [21] [22] A basic helix-loop-helix transcription factor, the activity and cellular abundance of Hif-1 is regulated by an oxygen-dependent proteolysis mechanism. At normal oxygen tensions, the a-subunit of the protein (Hif-1a) undergoes prolyl hydroxylation, which initiates recognition by the von Hippel-Lindau (Vhl) tumor suppressor protein, a component of the E3 ubiquitin ligase that targets Hif-1a for proteasomal degradation. When oxygen tensions fall below 5%, prolyl hydroxylation is inhibited; Hif1a accumulates and translocates to the nucleus where it forms a dimer with the Hif-1b subunit. In vitro studies suggest that Hif-1 regulates the expression of several hundred genes involved in angiogenic and metabolic responses, 21 and utilizes both direct promoter binding 23 as well as indirect mechanisms to alter gene expression. 24 Within bone, Hif-1 exerts distinct developmental functions. In developing bone, Hif-1 generated signals are required for angiogenesis, which appears to be necessary for initial specification of bone-forming osteoblasts. Consistent with this idea, mice lacking Hif-1a in osteoblasts and osteocytes develop poorly vascularized bones with reduced cortical and trabecular bone volume, while Hif overexpression results in highly vascularized and dense bone. [25] [26] As Hif-1a mutant mice mature, a second inhibitory function emerges such that Hif-1 acts as a negative regulator of bone formation. In this regard, cortical and trabecular bone volume normalize with age and Hif-1a mutants are more sensitive to mechanical stimuli. 27 In this study, we investigated the function of Hif-1a in osteo-anabolic signaling by assessing the effect of Hif-1a loss-of-function on bone formation in response to parathyroid hormone. In addition to hypoxia, Hif-1a expression is induced by a number of stimuli and signaling pathways critical for normal osteoblast function, including some that are used by PTH to increase bone formation. [27] [28] [29] Moreover, PTH stimulates vascular remodeling in bone, 30 which suggests two potential mechanisms by which Hif-1 might impact PTH-induced anabolism. Here, we demonstrate that PTH administration results in Hif-1a expression by osteoblasts both in vivo and in vitro, and that by interacting with b-catenin, Hif-1a suppresses the anabolic response. As a result, the removal of Hif-1a from osteoblasts and osteocytes sensitizes bone to PTH treatment by enhancing the activity of osteoblasts. These findings indicate that Hif-1a is a more general suppressor of osteo-anabolic signaling and acts to inhibit signals beyond those associated with mechanical loading.
MATERIALS AND METHODS

Generation of transgenic mice
The generation of mice lacking Hif-1a in osteoblasts and osteocytes (DHif-1a) was described previously. [26] [27] Briefly, OC-Cre mice 31 were crossed with mice in which the second exon of Hif-1a is floxed. 32 Mice containing Hif-2a-floxed alleles, 33 Vhl-floxed alleles 34 and mTOR-floxed (mTOR: mammalian target of rapamycin) alleles 35 Quantitative real-time PCR and chromatin immunoprecipitation Total RNA was extracted from osteoblasts or homogenized femurs using TRIzol (Invitrogen) and 1 mg was reverse transcribed using the iScript cDNA synthesis system (Bio-Rad, Hercules, CA, USA). Two microliters of cDNA was subjected to PCR amplification using the iQ SYBR Green Supermix (BioRad). Primer sequences were obtained from PrimerBank (http://pga.mgh.harvard.edu/primerbank/index.html).
Reactions were normalized to endogenous b-actin reference transcript. Chromatin immunoprecipitation assays were performed using an Agarose ChIP Kit (Pierce, Rockford, IL, USA) according to the manufacturer's instructions and a ChIP-qualified antibody specific for b -catenin (PAS-16192; Thermo Scientific, Waltham, MA, USA). Precipitated DNA (2 mL) was subjected to PCR amplification by qPCR and normalized to reference reactions utilizing input DNA. Primer sequences for the Axin2 promoter are available upon request.
Protein isolation and assays Protein was extracted from cultured osteoblasts in 0.1% Triton X-100 containing protease and phosphatase inhibitors. The extracts were separated on 10% SDS/polyacrylamide gels and transferred to PVDF (polyvinyl difluoride) membranes. Antibodies for Hif-1a (NB100-105), Hif-2a (NB100-122) and Hif-1b (NB100-124) were obtained from Novus Biological. Antibodies for phospho-Akt (S473, 9721), Akt (9272), phospho-p70 S6 kinase (9206), p70 S6 kinase (9202), phospho-Creb (9198), Creb (9197), phospho-Erk (9101), Erk (9107) and b -catenin (2698) were obtained from Cell Signaling Technologies, Danvers, MA, USA.
Bound antibodies were visualized using either the Supersignal West Femto or West Pico Substrates (Pierce). Coimmunoprecipitation was performed overnight at 4 6 C in a reaction containing 2 mg of antibody specific for Hif-1a (Novus) or b-catenin (Cell Signaling Technologies, San Diego, CA, USA).
Statistical analysis
Results are expressed as mean6s.e.m. All statistical tests were two-sided. A P-value less than 0.05 was considered significant. Comparability of two groups of data was assessed using a Student's t-test.
RESULTS
PTH stimulates Hif-1a expression in osteoblasts Mice that lack Hif-1a in osteoblasts and osteocytes (Hif1a flox/flox ; Oc-Cre TG/1 , hereafter referred to as DHif-1a)
exhibit early deficits in both cortical and trabecular bone architecture that are at least partially attributable to impairments in skeletal vascularization. [25] [26] As the mutant mice mature, bone architecture normalizes, 27 indicating that Hif-1a exerts distinct developmental functions and likely acts to suppress osteo-anabolic signaling. To assess this inhibitory function, we examined the influence of Hif-1a on the response of osteoblasts to PTH. To establish that Hif-1a regulates osteo-anabolic signaling in response to PTH, we first examined the ability of the hormone to induce the expression of Hif-1a in osteoblasts. In cultures of normoxic calvarial osteoblasts, PTH (10 nmol?L
21
) rapidly increased Hif-1a protein levels, with expression levels peaking between 2 and 4 h after stimulation and remaining elevated through 8 h of treatment ( Figure 1a ). Protein levels of Hif-2a and Hif-1b were not affected. However, desferoxamine, an iron chelator that inhibits the activity of the prolyl-hydroxylase enzymes that initiate the targeting of Hif-a subunits for proteasomal degradation, induced the expression of both Hif-1a and Hif-2a (Figure 1b) , indicating that the effects of PTH are specific for Hif-1a. PTH administration also increased Hif1a expression in vivo as PTH treated mice (40 mg?kg 21 ) exhibited robust expression of Hif-1a in osteoblasts lining trabecular bone surfaces, a subset of osteocytes, and marrow components (Figure 1c) , while saline treated animals exhibited only weak expression in these cell populations. Both in vitro (Figure 1d ) and in vivo (Figure 1e ), the levels of Hif-1a mRNA were unaffected by PTH stimulation, suggesting that the induction of Hif-1a protein occurs via a post-transcriptional mechanism.
cAMP/protein kinase A (PKA) signaling induces Hif-1a expression in response to PTH PTH could increase Hif-1a protein levels without affecting Hif-1a transcription by specifically enhancing Hif-1a transHif-1a suppresses PTH action JL Frey et al 3 lation or by inhibiting proteasomal degradation. Since PTH retained the capacity to increase Hif-1a protein levels in osteoblasts deficient for Vhl (data not shown), we focused on the induction of new Hif-1a synthesis. As expected, pretreatment of osteoblast cultures with cycloheximide, to inhibit new protein synthesis, abolished the effect of PTH on Hif-1a protein levels (Figure 2a and 2d) . Moreover, increases in the phosphorylation of Akt (S473) and p70 S6 kinase (Figure 2b ) indicated that PTH activates mTOR, a key regulator of Hif expression in response to anabolic signals. [39] [40] Adenoviral Cre-mediated disruption of mTOR expression in osteoblasts containing mTOR flox/flox alleles, via an 83% reduction in mTOR mRNA levels, completely inhibited the effect of PTH on Hif-1a protein (Figure 2c and 2d). We next explored the signaling mechanisms by which PTH activates mTOR and ultimately increases Hif-1a protein. Because an increase in cellular cAMP signaling is a primary response to PTH binding to its receptor, 6, 12 we initially assessed the effect of pharmacologically raising cAMP levels on mTOR activity and Hif-1a expression. Forskolin, which activates adenylyl cyclase, dose-dependently stimulated the phosphorylation of Akt and p70 S6 kinase (Figure 2e and 2f) , indicating that mTOR was activated, and increased the levels of Hif-1a protein (Figure 2g and 2h) . To confirm these results, we pre-treated osteoblast cultures with H-89 to antagonize the activity of PKA, the downstream mediator of cAMP signaling. This approach greatly impaired the ability of PTH to stimulate the phosphorylation of Akt and p70 S6 kinase (Figure 2i-2k) , even though baseline levels of p70 phosphorylation were increased by H-89, and abolished the increase in Hif-1a protein (Figure 2l and 2m) . Together, these data suggest a mechanism whereby PTH activates cAMP/PKA signaling which in turn activates the mTOR pathway to regulate Hif-1a expression.
DHif-1a mice are more sensitive to anabolic PTH treatment To directly assess the effect of Hif-1a expression on the anabolic response of bone to PTH, we generated cohorts of 10-week-old female control and DHif-1a mice and administered daily injections of PTH or saline, as a control, for 6 weeks. MicroCT analysis revealed equivalent trabecular bone architecture in the distal femur of saline treated control and DHif-1a mice, which is consistent with our previous study 27 that demonstrated a normalization of bone volume in Hif-1a mutants (Figure 3a Hif (Figure 3c ) and thickness (Figure 3d ). In Hif-1a mutants, PTH increased bone volume an additional 22.86% relative to the treated control mice (182.19% increase versus DHif-1a, saline-treated controls), due to significantly larger increases in trabecular thickness and slightly larger increases in trabecular number. PTH also significantly increased cortical bone thickness, but the effect was indistinguishable between control and Hif-1a mutant mice (data not shown). Likewise, increases in body weight were equivalent among control and Hif-1a mutant mice (data not shown). When we reduced the daily dose of PTH to 20 mg?kg 21 , the increase in trabecular bone volume in the mutant mice (182.79% increase versus DHif1a, saline-treated controls) was identical to that of the 40 mg?kg 21 treatment group, while the percent increase in the control mice was reduced by 29.91% (Figure 3a  and 3b) . Taken together, these data suggest that disrupting the expression of Hif-1a increases the sensitivity of bone to intermittent PTH. To understand the cellular basis for the enhanced anabolic response in DHif-1a mice, we performed dynamic histomorphometric and serological analyses of bone formation. Since all measures were equivalent in the saline-treated control and DHif-1a mice, results are presented as the relative increase above this baseline level (Figure 3e-3i) . PTH increased the mineralizing surface per bone surface to a similar extent in control and DHif-1a mice (Figure 3e ), but the mutant mice exhibited a 23.2% increase in mineral apposition rate while no effect of PTH on this parameter was observed in the control mice (Figure 3f ). This led to a greater overall increase in bone formation rate in the mutant mice relative to the control mice (Figure 3g) . Similarly, serum levels of P1NP (Figure 3h ), a marker of bone formation, were increased to a greater Hif-1a suppresses PTH action JL Frey et al 5 extent in the mutant mice relative to controls, while the levels of C-terminal telopeptide (Figure 3i ), a marker of bone resorption, were increased to a similar degree. Thus, the amplified sensitivity of Hif-1a mutant mice to PTH and augmented bone formation response appear to be due to an increase in the functional activity of individual osteoblasts.
Hif-1a antagonizes the actions of b-catenin after PTH stimulation Finally, we assessed cellular signaling mechanisms that might account for the increased responsiveness of Hif-1a mutant mice to PTH. Calvarial osteoblasts were isolated from Hif-1a flox/flox mice and infected with adenoviral constructs expressing Cre to eliminate Hif-1a expression (Figure 4a ) or green fluorescent protein as a control. We next examined the effect of eliminating Hif-1a expression on the activation of the primary PTH-responsive pathways, but the increase in cellular cAMP levels ( Figure 4b ) and the phosphorylation of Creb and Erk ( Figure 4c ) were similar in control and Hif-1a deficient osteoblasts. By contrast, the increase in Axin2 and Nkd2 mRNA levels was enhanced after PTH treatment in DHif-1a osteoblasts relative to those of controls (Figure 4d and 4e) , suggesting that the Results from e through i are presented as % change from baseline levels in saline-treated animals, which were equivalent in control and DHif-1a mice. *Pƒ0.05 vs. control mice with matched treatment. P1NP, amino pro-peptide of type 1 collagen; CTx, C-terminal telopeptide; s.c., subcutaneous.
Hif-1a suppresses PTH action JL Frey et al 6 activation of b-catenin was increased. 41 To test the specificity of this apparent inhibitory effect of Hif-1a on b-catenin activity, we overexpressed Hif-1a by eliminating the expression of Vhl (Figure 4f ), and as expected this genetic manipulation impaired the ability of PTH to increase the expression of Axin2 (Figure 4g ). The expression of Hif-1a in response to PTH did not alter the accumulation or nuclear localization of b-catenin (Figure 4h ), but rather Hif-1a directly interacted with b-catenin ( Figure 4i ) and acted to inhibit the binding of b-catenin to the promoter of target genes (Figure 4j ). We observed a similar effect in vivo as PTH produced a significant increase in Axin2 mRNA levels in the femurs of DHif-1a mice, but not those of control mice. These data imply that the enhanced bone formation response 
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ΔHif-1α Control Hif-1a suppresses PTH action JL Frey et al 7 evident in Hif-1a mutant mice stems from the elimination of Hif-1a-mediated suppression of b-catenin signaling.
DISCUSSION
In this study, we demonstrate that the transcription factor Hif-1a acts to suppress the anabolic actions of parathyroid hormone. Hif-1a protein levels were rapidly upregulated both in vitro and in vivo by PTH stimulation and mice rendered deficient for Hif-1a in osteoblasts and osteocytes were more responsive to intermittent administration of the hormone. The more dramatic increase in bone formation evident in Hif-1a mutant mice appears to result from an increase in the performance of individual osteoblasts secondary to an enhancement of b-catenin target gene expression.
In addition to hypoxia, Hif-1a is induced by a number of anabolic signals relevant to bone metabolism. Mechanical loading, 42 growth factors and paracrine factors like prostaglandins [43] [44] [45] all increase Hif-1a protein levels. Some of these factors have also been implicated in the anabolic response of bone to PTH. Insulin-like growth factor-1, for instance, induces Hif-1a expression, 46 and removal of its receptor diminishes bone formation in response to the hormone. 13 While insulin-like growth factor-1 might partially contribute to the induction of Hif-1a after PTH stimulation, the rapid effect we observed suggests a more direct effect on Hif-1a synthesis. Indeed, our data suggest that PTH activates cAMP/PKA signaling to increase the activity of mTOR, which can directly regulate Hif-1a translation. [39] [40] 47 While not directly examined here, studies in other tissues indicate that PKA can activate mTOR signaling via a number of mechanisms, including the engagement of PI3K/Akt signaling and the phosphorylation of TOR complex components. [48] [49] As alluded to above, mTOR signaling has also been demonstrated to be an important component of the anabolic response of bone to PTH, as rapamycin treatment inhibits the increase in trabecular bone volume resulting from high-dose PTH administration by reducing osteoblastic activity. 29 In light of our data, it would appear that mTOR plays a dual role in the response of bone to intermittent PTH, facilitating anabolism while also establishing a mechanism to suppress anabolic signaling via induction of Hif-1a expression. We focused our analysis on the effects of Hif-1a on b-catenin signaling because of its well-documented anabolic role in the skeleton, but we cannot rule out the possibility that Hif-1a also regulates the expression of factors that inhibit mTOR signaling. 50 Even though angiogenesis is a well-explored response to increased Hif-1a signaling and PTH has been shown to induce skeletal vascular remodeling, 30 it does not appear that this effect factors into the anabolic response we observed. If vascular remodeling and the relocalization of blood vessels to sites of new bone formation were regulated by Hif-1a, we would have expected the disruption of Hif-1a expression to impair the osteo-anabolic response. However, we cannot completely rule out a compensatory effect of the closely related Hif-2a. Rather, as we have suggested previously, 27 it is likely that Hif-1a assumes an inhibitory role in the mature skeleton to prevent unchecked anabolic signaling and the generation of signals that impinge on cellular function. Hif-1a is induced by reactive oxygen species, and Hif-1-generated signals in turn reduce new oxidant production. [51] [52] [53] [54] Therefore, induction of Hif-1a may ensure cellular longevity and facilitate cellular repair after the generation of cellular stressors during an anabolic response.
The results presented here are consistent with our previous finding that Hif-1a acts to inhibit the anabolic response to a tibia-loading regime and potentially does so by suppressing b-catenin activity. 27 However, several important differences exist when the cellular basis of each response is considered. Our mechanical loading study demonstrated that Hif-1a inhibited the anabolic response in the cortical bone envelope, but in these studies, PTH produced similar increases in cortical bone thickness in control and mutant mice. Likewise, the number of osteoblasts activated by mechanical loading was greatly increased in Hif-1a mutant mice, but the effect of PTH on bone formation in these mice appears to be related to a larger increase in the functional output of individual osteoblasts. Here, the mineralizing surface was similarly enhanced in control and mutant mice, but the mineral apposition rate and P1NP levels were enhanced by the genetic removal of Hif-1a. While we cannot exclude the possibility that the differential effects are simply the result of different bone compartments, these data suggest that the suppressive actions of Hif-1a may be dependent on the cellular context and the stimulus. Nonetheless, the significant increase in the anabolic effect of each of these stimuli suggests that Hif-1a activity could be targeted in therapeutic paradigms. Previous studies have identified pharmacological molecules that impair Hif-1a transcriptional activity or interaction with binding partners. [55] [56] [57] While these studies have primarily focused on the prevention of tumor growth and tumorinduced angiogenesis, these agents or molecules with similar functions could be adapted to enhance anabolic therapies in bone. After prolonged treatment with intermittent PTH, markers of bone formation begin to decline, suggestive of the development of a resistance to the anabolic effects of the therapy. [58] [59] Whether increased expression of Hif-1a contributes to this effect will require additional studies. However, our studies suggest that an agent that inhibits the expression of Hif-1a or impairs the interaction of Hif-1a and b-catenin could be used to lower
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In summary, our studies support a role for Hif-1a as a negative regulator of osteo-anabolic signaling. In early development, Hif-1a functions in bone cells to facilitate the vascularization of long bones, a process that is required for normal bone acquisition. As bone matures, Hif-1a assumes a new function that likely acts to restrain osteoblast and osteocyte activity and does so by interfering with a key component of the Wnt signaling pathway. Our studies provide a broader understanding of the molecular physiology of Hif-1a in bone cells and may lead to the design of strategies to augment skeletal therapeutics.
